Presently, there is no targeted treatment available for human respiratory syncytial virus (hRSV) infection other than the supportive care to mitigate the signs of and symptoms. Antiviral drug development and RSV vaccine is expected to play a critical role in overall reduction of RSV infections globally.
In this whitepaper, we present several case studies performed in clinically relevant mouse model to assess the critical characteristics of potential RSV therapeutics. In summary, this article includes in-house as well as client-sponsored study data established over several years using BALB/c mouse models. These studies generated clinically pertinent information for proper screening of new vaccines and antivirals.